Cost-effectiveness of full coverage of aromatase inhibitors for Medicare beneficiaries with early breast cancer

Cancer

Volumn 119, Issue 13, 2013, Pages 2494-2502

  Ito, Kouta ^a   Elkin, Elena ^b   Blinder, Victoria ^b   Keating, Nancy ^a,c   Choudhry, Niteesh ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^c HARVARD MEDICAL SCHOOL   (United States)

Author keywords

aromatase inhibitors; breast neoplasms; Medicare; medication adherence

Indexed keywords

ANASTROZOLE; AROMATASE INHIBITOR; EXEMESTANE; GENERIC DRUG; LETROZOLE; TAMOXIFEN;

ADJUVANT THERAPY; ARTICLE; BREAST CANCER; CANCER RECURRENCE; CANCER STAGING; CANCER SURVIVAL; COHORT ANALYSIS; COST CONTROL; COST EFFECTIVENESS ANALYSIS; DISEASE FREE SURVIVAL; DRUG COST; HEALTH CARE UTILIZATION; HEALTH INSURANCE; HIDDEN MARKOV MODEL; HUMAN; MEDICARE; MENOPAUSE; OVERALL SURVIVAL; PATIENT COMPLIANCE; PRESCRIPTION; PRIORITY JOURNAL; QUALITY ADJUSTED LIFE YEAR;

AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; AROMATASE INHIBITORS; BREAST NEOPLASMS; COST SHARING; COST-BENEFIT ANALYSIS; DISEASE PROGRESSION; DRUG COSTS; FEMALE; HUMANS; INSURANCE COVERAGE; MARKOV CHAINS; MEDICARE; MEDICATION ADHERENCE; NEOPLASM STAGING; POSTMENOPAUSE; QUALITY-ADJUSTED LIFE YEARS; TUMOR MARKERS, BIOLOGICAL; UNITED STATES;

EID: 84879081748     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.28084     Document Type: Article

References (57)

1. Burstein HJ, Prestrud AA, Seidenfeld J, et al. American Society of Clinical Oncology clinical practice guideline: update on adjuvant endocrine therapy for women with hormone receptor-positive breast cancer. J Clin Oncol. 2010; 28: 3784-3796.
2. National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology. Breast cancer; version I, 2012. Available at: http://www.nccn.org/professionals/physician-gls/pdf/breast.pdf. Accessed February 1, 2013.
3. Dowsett M, Cuzick J, Coates A, et al. Meta-analysis of breast cancer outcomes in adjuvant trials of aromatase inhibitors versus tamoxifen. J Clin Oncol. 2010; 28: 509-518.
4. Partridge AH, LaFountain A, Mayer E, Taylor BS, Winer E, Asnis-Alibozek A,. Adherence to initial adjuvant anastrozole therapy among women with early breast cancer. J Clin Oncol. 2008; 26: 556-562.
5. Hershman DL, Kushi LH, Shao T, et al. Early discontinuation and nonadherence to adjuvant hormonal therapy in a cohort of 8,769 early stage breast cancer patients. J Clin Oncol. 2010; 28: 4120-4128.
6. Sedjo RL, Devine S,. Predictors of non-adherence to aromatase inhibitors among commercially insured women with breast cancer. Breast Cancer Res Treat. 2011; 125: 191-200.
7. Hershman DL, Shao T, Kushi LH, et al. Early discontinuation and non-adherence to adjuvant hormonal therapy are associated with increased mortality in women with breast cancer. Breast Cancer Res Treat. 2011; 126: 529-537.
8. Sabate E,. Adherence to Long-Term Therapies: Evidence for Action. Geneva, Switzerland: World Health Organization; 2003.
9. Agency for Healthcare Research and Quality. Closing the quality gap series: comparative effectiveness of medication adherence interventions. Available at: http://www.effectivehealthcare.ahrq.gov/ehc/products/296/764/ Medication-Adherence-Protocol-20110818.pdf. Accessed February 1, 2013.
10. Haynes RB, Ackloo E, Sahota N, McDonald HP, Yao X,. Interventions for enhancing medication adherence [serial online]. Cochrane Database Syst Rev. 2008;(4): CD000011.
11. Ell K, Vourlekis B, Xie B, et al. Cancer treatment adherence among low-income women with breast or gynecologic cancer: a randomized controlled trial of patient navigation. Cancer. 2009; 115: 4606-4615.
12. GoodRx. Available at: http://www.goodrx.com. Accesses February 1, 2013.
13. Q1Medicare.com. 2012 Drug finder: search for your prescription drug across all Medicare pt D or Medicare Advantage plans. Available at: http://www.q1medicare.com/PartD-SearchPDPMedicarePartDDrugFinder.php. Accessed February 1, 2013.
14. Neugut AI, Subar M, Wilde ET, et al. Association between prescription copayment amount and compliance with adjuvant hormonal therapy in women with early breast cancer. J Clin Oncol. 2011; 29: 2534-2542.
15. Riley GF, Warren JL, Harlan LC, Blackwell SA,. Endocrine therapy use among elderly hormone receptor-positive breast cancer patients enrolled in Medicare pt D [serial online]. Medicare Medicaid Res Rev. 2011; 1: E1-E26.
16. Choudhry NK, Rosenthal MB, Milstein A,. Assessing the evidence for value-based insurance design. Health Aff (Millwood). 2010; 29: 1988-1994.
17. Choudhry NK, Avorn J, Glynn RJ, et al. Full coverage for preventive medications after myocardial infarction. N Engl J Med. 2011; 365: 2088-2097.
18. Fendrick AM, Martin JJ, Weiss AE,. Value-based insurance design: more health at any price. Health Serv Res. 2012 (1 pt 2); 47: 404-413.
19. Ito K, Blinder VS, Elkin EB,. Cost effectiveness of fracture prevention in postmenopausal women who receive aromatase inhibitors for early breast cancer. J Clin Oncol. 2012; 30: 1468-1475.
20. Partridge AH, Wang PS, Winer EP, Avorn J,. Nonadherence to adjuvant tamoxifen therapy for primary breast cancer. J Clin Oncol. 2003; 21: 602-606.
21. Owusu C, Buist DS, Field TS, et al. Predictor of tamoxifen discontinuation among older women with estrogen receptor-positive breast cancer. J Clin Oncol. 2008; 26: 549-555.
22. DeSantis D, Siegel R, Bandi P, Jemal A,. Breast cancer statistics. 2011. CA Cancer J Clin. 2011; 61: 409-418.
23. Wolters Kluwer Pharmacy Solutions. Source Pharmaceutical Audit Suite. Available at: http://s01.pharma.wkhealth.com/AuditSuite/. Accessed February 1, 2013.
24. Delea TE, Karnon J, Sofrygin O, Thomas SK, Papo NL, Barghout V,. Cost-effectiveness of letrozole versus tamoxifen as initial adjuvant therapy in hormone receptor-positive postmenopausal women with early stage breast cancer. Clin Breast Cancer. 2007; 7: 608-618.
25. Regan MM, Neven P, Giobbie-Hurder A, et al. Assessment of letrozole and tamoxifen alone and in sequence for postmenopausal women with steroid hormone receptor-positive breast cancer: the BIG 1-98 randomized controlled trial at 8.1 years median follow-up. Lancet Oncol. 2011; 12: 1101-1108.
26. Cuzick J, Sestak I, Baum M, et al. Effect of anastrozole and tamoxifen as adjuvant treatment for early stage breast cancer: 10-year analysis of the ATAC trial. Lancet Oncol. 2010; 11: 1135-1141.
27. Davies C, Godwin J, Gray R, et al. Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomized trials. Lancet. 2011; 378: 771-784.
28. National Center for Health Statistics. United States Life Tables, 2006. Available at: http://www.cdc.gov/nchs/data/nvsr/nvsr58/nvsr58-21.pdf. Accessed February 1, 2013.
29. Peasgood T, Ward SE, Brazier J,. Health state utility values in breast cancer. Expert Rev Pharmacoecon Outcomes Res. 2010; 10: 553-566.
30. Lamerato L, Havstad S, Gandhi SK, Jones D, Nathanson D,. The economic burden of breast cancer recurrence: findings from a retrospective analysis of health system data. Cancer. 2006; 106: 1875-1882.
31. Hayman JA, Langa KM, Kabeto MU, et al. Estimating the cost of informal caregiving for elderly patients with cancer. J Clin Oncol. 2001; 19: 3219-3225.
32. US Department of Labor. US Consumer Price Index for medical care for all urban consumers. Available at: http://data.bls.gov/cgi-bin/surveymost. Accessed February 1, 2013.
33. Gold MR, Siegel JE, Russel LB, et al. Cost-Effectiveness in Health and Medicine. New York: Oxford University Press; 1996.
34. Briggs A, Sculpher M, Claxton K,. Decision Modelling for Health Economic Evaluation. Oxford: Oxford University Press; 2006.
35. Dunnwald LK, Rossing MA, Li CK,. Hormone receptor status, tumor characteristics, and prognosis: a prospective cohort of breast cancer patients [serial online]. Breast Cancer Res. 2007; 9: R6.
36. Goldman DP, Joyce GF, Zheng Y,. Prescription drug cost sharing. Associations with medication and medical utilization and spending and health. JAMA. 2007; 298: 61-69.
37. Meropol NJ, Schrag D, Mulvey TM, et al. American Society of Clinical Oncology guidance statement: the cost of cancer care. J Clin Oncol. 2009; 27: 3868-3874.
38. Avalere Health, American Cancer Society Cancer Action Network. Cost sharing for cancer patients in Medicare, 2009. Available at: http://action.acscan.org/site/DocServer/Avalere-ACS-CAN-Part-D-study-final- version-with-Sarah-s-.pdf/482831466?docID=10441&verID=1. Accessed February 1, 2013.
39. Goldman DP, Joyce GF, Escarce JJ, et al. Pharmacy benefits and the use of drugs by the chronically ill. JAMA. 2004; 291: 2344-2350.
40. Trivedi AN, Rakowski W, Ayanian JZ,. Effect of cost sharing on screening mammography in Medicare health plans. N Engl J Med. 2008; 358: 375-383.
41. Swartz K,. Cost-sharing: effect on spending and outcomes. Robert Wood Johnson Foundation Synthesis Project Report No. 20, December 2010. Available at: http://www.rwjf.org/files/research/121710.policysynthesis.costsharing.rpt.pdf. Accessed February 1, 2013.
42. Pezzin LE, O'Neil MB, Nattinge AB,. The economic consequences of breast cancer adjuvant hormonal treatments. J Gen Intern Med. 2009 (suppl 2): 24: S446-S450.
43. USA Today, Kaiser Family Foundation, Harvard School of Public Health. National survey of households affected by cancer. Available at: http://www.kff.org/kaiserpolls/7590.cfm. Accessed February 1, 2013.
44. Kaiser Family Foundation: The Medicare pt D coverage gap: costs and consequences in 2007. Available at: http://www.kff.org/medicare/7811.cfm. Accessed February 1, 2013.
45. Polinski JM, Shrank WH, Huskamp HA, Glynn RJ, Liberman JN, Schneeweiss S,. Change in drug utilization during a gap in insurance coverage: an examination of the Medicare pt D coverage gap [serial online]. PLoS Med. 2011; 8: e1001075.
46. Braithwaite RS, Rosen AM,. Linking cost sharing to value: an unrivaled yet unrealized public health opportunity. Ann Intern Med. 2007; 146: 602-605.
47. Fendrick AM, Smith DG, Chernew ME, Shah SN,. A benefit-based copay for prescription drugs: patient contribution based on total benefits, not drug acquisition cost. Am J Manag Care. 2001; 7: 861-867.
48. Chernew ME, Rosen AB, Fendrick AM,. Value-based insurance design. Health Aff (Millwood). 2007; 26: w195-w203.
49. Patient Protection and Affordable Care Act of 2010, Pub L No. 111-148. Available at: http://www.gpo.gov/fdsys/pkg/PLAW-111publ148/pdf/PLAW-111publ148. pdf. Accessed February 1, 2013.
50. de Souza JA, Ratain MJ, Fendrick AM,. Value-based insurance design: aligning incentives, benefits, and evidence in oncology. J Natl Compr Canc Netw. 2012; 10: 18-23.
51. Rosen AB, Hamel MB, Weinstein MC, Cutler DM, Fendrick AM, Vijan S,. Cost-effectiveness of full Medicare coverage of angiotensin-converting enzyme inhibitors for beneficiaries with diabetes. Ann Intern Med. 2005; 143: 89-99.
52. Choudhry NK, Patrick AR, Antman EM, Avorn J, Shrank WH,. Cost-effectiveness of providing full drug coverage to increase medication adherence in post-myocardial infarction Medicare beneficiaries. Circulation. 2008; 117: 1261-1268.
53. Baithwaite RS, Omokaro C, Justice AC, Nucifora K, Roberts MS,. Can broader diffusion of value-based insurance design increase benefits from US health care without increasing cost? Evidence from a computer simulation model [serial online]. PLoS Med. 7: e100234, 2010.
54. Davidoff A, Lopert R, Stuart B, Shaffer T, Lloyd JT, Shoemaker JS,. Simulated value-based insurance design applied to statin use by Medicare beneficiaries with diabetes. Value Health. 2012; 15: 404-411.
55. Neumann PJ, Rosen AB, Weinstein MC,. Medicare and cost-effectiveness analysis. N Engl J Med. 2005; 353: 1516-1522.
56. Murphy CC, Bartholomew LK, Carpentier MY, Bluethman SM, Vernon SW,. Adherence to adjuvant hormonal therapy among breast cancer survivors in clinical practice: a systematic review. Breast Cancer Res Treat. 2012; 134: 459-478.
57. Henry NL, Azzouz F, Desta Z, et al. Predictors of aromatase inhibitor discontinuation as a result of treatment-emergent symptoms in early stage breast cancer. J Clin Oncol. 2012; 30: 936-942.